Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Drug Profile

Neurotrophic factor-producing mesenchymal stem cell therapy - BrainStorm Cell Therapeutics

Alternative Names: Autologous bone marrow derived mesenchymal stem cell therapy - BrainStorm Cell therapeutics; Autologous MSC-NTF; Bone-marrow-derived-mesenchymal-stem-cells-BrainStorm; GDNF therapy; GDNf-stem-cell-therapy-BrainStorm-Cell-Therapeutics; Glial-cell-line-derived neurotrophic factor stem cell therapy - BrainStorm Cell Therapeutics; Glial-cell-line-derived-neurotrophic-factor-stem-cell-therapy-BrainStorm; MSC-NTF; MSC-NTF-BrainStorm-Cell-Therapeutics; Neurotrophic factor-secreting stem cell therapy; Neurotrophic-factor-producing-adult-stem-cell-therapy-BrainStorm; NurOwn; NurOwn-GDNF-therapy; NurOwn™ program one

Latest Information Update: 16 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tel Aviv University
  • Developer Brainstorm Cell Therapeutics; Hadassah Medical Organization; Tel Aviv University
  • Class Analgesics; Antiparkinsonians; Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Amyotrophic lateral sclerosis
  • Phase II Multiple sclerosis
  • Preclinical Autistic disorder
  • No development reported Huntington's disease; Parkinson's disease; Sciatica; Spinal cord injuries

Most Recent Events

  • 11 Oct 2019 Brainstorm-Cell Therapeutics completes enrolment in a phase-III clinical trials in Amyotrophic lateral sclerosis in USA (Intrathecal) (NCT03280056)
  • 07 Oct 2019 BrainStorm Cell Therapeutics receives patent allowance for neurotrophic factor-producing mesenchymal stem cell therapy (NurOwn®) in USA
  • 28 May 2019 The Israeli Ministry of Health approves NurOwn® to patients with Amyotrophic lateral sclerosis under Hospital Exemption pathway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top